ACTN1

ACTN1 encodes α-actinin-1, a non-muscle actin-crosslinking protein whose core function is to bundle and organize the F-actin cytoskeleton, an activity required for proper cellular architecture across megakaryocytes, cardiomyocytes, and endothelial cells [PMID:23434115, PMID:bio_10.1101_2025.03.28.645933, PMID:41605926]. Pathogenic missense mutations distributed across all major structural domains — the actin-binding domain (ABD), the spectrin-like rod repeats, and dimerization-relevant regions — disorganize the actin cytoskeleton, produce abnormal proplatelet formation in megakaryocytes, and cause autosomal dominant macrothrombocytopenia (PMID:23434115, PMID:24069336, PMID:26453073, PMID:31237726). In cardiomyocytes ACTN1 localizes to focal adhesions and is non-redundantly required for focal adhesion maturation and sarcomere Z-line assembly, a function that ACTN2 cannot substitute [PMID:bio_10.1101_2025.03.28.645933]. ACTN1 abundance is tightly controlled at multiple levels: Cullin-3-mediated ubiquitin-dependent degradation limits its accumulation during myogenesis (PMID:30990797), the USP14 deubiquitinase stabilizes the protein by removing ubiquitin chains (PMID:41291211), STAT5A transcriptionally sustains its expression to maintain F-actin and mitochondrial architecture [PMID:bio_10.1101_2025.05.26.656095], and miR-129-5p represses it post-transcriptionally (PMID:38566572). Beyond structural crosslinking, ACTN1 functions in signaling and tumor progression: it binds MOB1 to suppress Hippo/LATS1/YAP signaling (PMID:33413564), engages integrin β1 to activate FAK/PI3K/AKT and, via enhanced MYH9–GSK-3β interaction, drives β-catenin signaling in a c-Myc-coupled feedback loop (PMID:38057867), and partners with ITGA5 to promote proliferation and invasion (PMID:36742137). Its actin-bundling activity is further modulated by interacting proteins including LLGL2, which alters its localization (PMID:38136424), and PDLIM5, which cooperates with ACTN1/ACTN4 to drive filopodia formation and sprouting angiogenesis (PMID:41605926).

1. 2013 High

   Established that ACTN1 mutations cause human disease by disrupting megakaryocyte cytoskeletal organization, answering how a cytoskeletal crosslinker links to platelet production defects.

   Evidence Transfection of ABD mutations in CHO cells and retroviral transduction of mouse fetal liver-derived megakaryocytes with morphological analysis of proplatelet formation

   PMID:23434115 PMID:24069336

   Open questions at the time

   • Did not resolve which actin-bundling biophysical parameter is altered by each mutation
   • Restricted to ABD-domain mutations
2. 2015 Medium

   Extended the disease mechanism beyond the ABD by showing rod-domain (SLR2) and dimerization-hindering mutations also disorganize actin, indicating multiple structural routes to loss of function.

   Evidence Immunofluorescence of transfected CHO cells and in vitro expression of rod-domain variants with actin network morphology analysis

   PMID:26453073 PMID:31237726

   Open questions at the time

   • Single-method (IF) for some variants
   • Quantitative biophysical effect on dimerization not directly measured
3. 2002 Medium

   Revealed isoform diversity by identifying a brain-specific ACTN1 splice variant, raising the question of tissue-specific cytoskeletal functions.

   Evidence RT-PCR and in situ hybridization in rat brain with developmental and regional expression analysis

   PMID:12099693

   Open questions at the time

   • Functional role of the brain-specific isoform not determined
   • No binding-partner or activity data for this isoform
4. 2011 Medium

   Placed ACTN1 in a defined muscle-associated complex with FHL1 and PDLIM1, establishing physical partnerships in cardiac tissue.

   Evidence Tandem affinity purification with LC-MS, reciprocal IP from mouse heart ventricles, and 3D fluorescence microscopy in cardiomyocytes

   PMID:21246116

   Open questions at the time

   • Functional consequence of the complex not tested
   • Stoichiometry and direct binary contacts unresolved
5. 2019 High

   Showed that ACTN1 protein levels must be actively restrained, identifying Cullin-3-mediated degradation as essential for myogenesis and neuromuscular junction development.

   Evidence Cullin-3 knockout mice, C2C12 overexpression with fusion and acetylcholine receptor clustering assays, and proteomic detection of ACTN1 accumulation

   PMID:30990797

   Open questions at the time

   • Direct E3-substrate ubiquitination biochemistry not fully reconstituted
   • Adaptor selecting ACTN1 within Cullin-3 complex not defined
6. 2021 Medium

   Connected ACTN1 to growth-control signaling by showing it binds MOB1 to suppress Hippo/LATS1/YAP and promote tumor growth.

   Evidence Co-IP, p-LATS1/p-YAP western blotting, ACTN1 knockdown in HCC cells, xenograft models, and YAP pharmacological inhibition rescue

   PMID:33413564

   Open questions at the time

   • Single lab without reciprocal in vivo genetic validation
   • Whether actin-bundling activity is required for MOB1 inhibition unknown
7. 2023 Medium

   Defined ACTN1 as a node in oncogenic adhesion/Wnt signaling via integrin β1/FAK/PI3K/AKT, MYH9-dependent GSK-3β degradation driving β-catenin, and an ITGA5-dependent invasion axis.

   Evidence Reciprocal Co-IP, IP-mass spectrometry, dual-luciferase reporter, siRNA rescue, and xenograft/patient-derived xenograft models in HNSCC

   PMID:36742137 PMID:38057867

   Open questions at the time

   • Multiple signaling claims rest on single-lab data
   • Direct versus indirect nature of ACTN1–GSK-3β coupling not separated
8. 2024 Medium

   Added post-transcriptional control by demonstrating miR-129-5p directly represses ACTN1 to limit anchorage-independent growth.

   Evidence 3'UTR luciferase reporter, RT-qPCR, miR-129-5p overexpression, and anchorage-independent growth assay in HPV-transformed keratinocytes

   PMID:38566572

   Open questions at the time

   • In vivo relevance of the miRNA-ACTN1 axis untested
   • Single cellular context
9. 2023 Medium

   Showed ACTN1 function can be modulated by localization rather than abundance, with LLGL2 redirecting ACTN1 to impair actin bundling and suppress ovarian cancer invasion.

   Evidence IP-mass spectrometry, LLGL2 overexpression/knockdown, migration/invasion assays, and in vivo metastasis model

   PMID:38136424

   Open questions at the time

   • Mechanism by which LLGL2 relocalizes ACTN1 unresolved
   • Direct binding interface not mapped
10. 2025 Medium

    Identified USP14 as the stabilizing deubiquitinase counterbalancing ACTN1 degradation, tying ACTN1 abundance to mesenchymal glioblastoma phenotypes.

    Evidence Ubiquitination assay, USP14 inhibition with IU1, western blotting, and intracranial xenograft models

    PMID:41291211

    Open questions at the time

    • Direct USP14–ACTN1 binding not biochemically reconstituted
    • Relationship to Cullin-3 pathway not co-analyzed
11. 2025 Medium

    Positioned ACTN1 as the downstream effector of a STAT5A–actin–mitochondria axis, linking transcriptional control to cytoskeletal and mitochondrial integrity.

    Evidence STAT5A/B knockout with ACTN1 ectopic rescue, live-cell imaging, mitochondrial morphology, DRP1 recruitment, and cGAS-STING/IFN assays (preprint)

    PMID:bio_10.1101_2025.05.26.656095

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • Direct STAT5A binding to the ACTN1 promoter not shown
12. 2025 Medium

    Demonstrated non-redundant ACTN1 function at cardiomyocyte focal adhesions required for sarcomere assembly, distinguishing it from ACTN2.

    Evidence siRNA knockdown, vinculin/paxillin live-cell imaging, and isoform-specific rescue with ACTN1 versus ACTN2 in hiPSC-derived cardiomyocytes (preprint)

    PMID:bio_10.1101_2025.03.28.645933

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • Molecular basis for ACTN1 vs ACTN2 non-redundancy undefined
13. 2026 Medium

    Showed PDLIM5 cooperates with ACTN1/ACTN4 to drive F-actin bundling, filopodia formation, and sprouting angiogenesis, defining a partner that activates ACTN1's bundling function.

    Evidence Co-IP with domain mapping (PDLIM5 S593/F596), endothelial-specific Pdlim5 knockout, filopodia/F-actin imaging, and in vivo tumor vascular assays

    PMID:41605926

    Open questions at the time

    • Direct ACTN1 contribution not separated from ACTN4
    • Whether PDLIM5 alters bundling kinetics biophysically untested
14. 2026 Medium

    Established ACTN1 as a druggable target whose enhanced F-actin affinity stabilizes endothelial junctions, identifying lobetyolin as a direct binder.

    Evidence Chemical proteomics, molecular docking, endothelial barrier assays, and an in vivo acute lung injury mouse model

    PMID:42202915

    Open questions at the time

    • Binding site on ACTN1 not crystallographically defined
    • Selectivity over ACTN4 not established

• How the multiple abundance-control pathways (Cullin-3, USP14, STAT5A, miR-129-5p) are integrated, and whether ACTN1's signaling roles depend on or are separable from its actin-bundling activity, remain unresolved.
• No unified model linking degradation, stabilization, and transcriptional control
• Structure-function separation of crosslinking versus signaling not addressed
• No high-resolution structure of mutant ACTN1 explaining domain-specific cytoskeletal failure